Biotech Values

[ghmm]

http://tinyurl.com/3y4hyp
Roche got an 8% SVR rate using Pegasys in non-responders to prior Peg-Intron. This was raised to 16% when second-line therapy was continued out to 72 weeks.

SGP got a 23% SVR rate using Peg-Intron in a mixed pool of non-responders/relapsers to prior Pegasys/Intron-A.

The Roche trial above is the more applicable trial with respect to what VRTX/JNJ are trying to do.

http://tinyurl.com/2ehorv


Dew,

Do you think if Prove-3 is in the 16% range that would be compelling enough for approval for that patient population just on the 2B results? TIA